![]()
Greetings! Since I’m sure many of you are returning from this year’s BIO International Convention, it felt fitting to broaden this week’s editorial focus to examine the industry developments, trends, and factors shaping biopharma in 2026.
It’s that time of the year when industry outlooks start getting measured against reality. So, I gathered my fellow editors on the podcast to wax on how the year is progressing and discuss the industry’s major developments thus far into 2026. If you’re interested in listening to that full editorial roundtable, click here.
In case you missed it, GlobalData’s “May 2026 CDMO Opportunities And Threats Report” is now available, which identifies CDMOs that may be impacted by key events affecting their clients (e.g., acquisitions, licenses, approvals, etc.).
While you’re at it, listen to the newest episode of “Better Biopharma,” featuring Noveome Biotherapeutics’ Larry Brown, Sc.D., where we talk about the company’s first-of-its-kind secretome therapy. Brown explains the story behind this novel therapy, the GMP manufacturing process Noveome developed to produce it, and the CMC challenges it faces from a regulatory perspective.
Before you go, be sure to check out some selected content from our partners below!
Tyler Menichiello
Chief Editor, Bioprocess Online
Greetings! Since I’m sure many of you are returning from this year’s 
